At screening, a genotypic level of resistance test was required in patients with latest HIV-1 acquisition. Screening for the HLA-B*5701 allele was permitted but not required. Patients were randomly designated to receive one of four oral once-daily regimens: 600 mg of efavirenz or 300 mg of atazanavir plus 100 mg of ritonavir provided with either 600 mg of abacavir plus 300 mg of lamivudine or 300 mg of tenofovir DF plus 200 mg of emtricitabine . The analysis was double-blinded in regards to to the NRTIs. <100,000 copies per milliliter), by using a permuted-block design with dynamic balancing based on the primary institution. Screening of HIV-1 RNA levels was performed at any laboratory accredited beneath the Clinical Laboratory Improvement Amendments.The primary analysis compared PCR-positive case individuals with PCR-negative controls, and the secondary evaluation compared PCR-positive case sufferers with matched handles. We considered the comparison with PCR-negative handles to be primary because it minimized the potential biases linked to the general propensity to use health care and the specific propensity of parents and physicians to test for pertussis. We fit conditional logistic-regression models to estimate the result of each additional year after receipt of the 5th DTaP dose in the odds of a positive PCR check for pertussis. For the primary analysis, we conditioned the logistic model on blocks of calendar time . We included covariates to regulate for age , sex, medical clinic , and race or ethnic group .